Chemomab (CMMB) news
Recent news
Chemomab Therapeutics Ltd - Nebokitug RA Phase 2 clinical trial expected to begin in H1 2027 and read out in H1 2028
AInvest Wire · Aug 19, 2026Chemomab Therapeutics Q2 EPS USD -0.003
Chemomab Therapeutics Ltd. (CMMB) reported an EPS of -USD 0.003 for the second quarter of 2025, reflecting continued financial challenges for the biopharmaceutical company based in Tel Aviv, Israel. The company’s cash and cash equivalents declined from $6.07 million at the end of 2024 to $5.45…
AInvest Wire · Aug 19, 2026Chemomab Therapeutics announces second quarter 2026 financial results and provides corporate update
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) reported its second quarter 2026 financial results and provided a corporate update, highlighting progress in its clinical development programs and financial position. The company continues to advance its lead candidate, nebokitug, a first-in-class…
AInvest Wire · Aug 19, 2026Chemomab Therapeutics: combined company to operate as Scipher Medicine Corporation & trade on Nasdaq under ticker symbol “SCIP”
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) has been granted an additional 180-day compliance period by Nasdaq to meet the minimum bid price requirement of $1.00 per share. The company now has until November 4, 2024, to regain compliance with the Nasdaq Marketplace Rule 5550(a)(2). If the closing bid…
AInvest Wire · Jul 8, 2026Chemomab: combined company valued at $150 mln before concurrent $30 million private placement from top-tier investors
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the development of therapeutics for fibro-inflammatory diseases, has continued to strengthen its financial position through a series of strategic capital-raising initiatives. In July 2024, the company…
AInvest Wire · Jul 8, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.